Categories: BlogIPO

Glenmark Life Sciences IPO : Highlights and Financial Information

Glenmark Life Sciences initiated its operations in 2011. It is the leader in the manufacturing of the API. It produces APIs for multiple fields of diagnosis. The company also functions into contract based development and manufacturing of operations. The company exports to many countries like Japan, Latin America, North America and Europe. There are a total of 4 manufacturing facilities of the company in Ankleshwar, Kurkumbh, Dahej, Mohol.

IPO DETAILS

The Glenmark Life Sciences IPO is set to launch on 27th July, 2021. The subscription timeline extends till 29th July, 2021. The size for the IPO is 1513.60 Crore Rs. Shares issued through Offer for sale are 453.60 Crore Rs. Shares worth Rs. 1060 Crore are issued through Fresh issue. The minimum lot size is shares and the price is set at 695 Rs. – 720 Rs./ share. The company is going to get listed at both the exchanges NSE and BSE. The face value per share is Rs. 2 and this is a book built issue. The registrar for the company is Karvy Fintech Private Limited.

TABULAR REPRESENTATION OF IPO DETAILS

IPO OPENING DATE	27th July, 2021
IPO CLOSING DATE	29th July, 2021
ISSUE TYPE	Book Built Issue
Face Value per share	2 Rs. per share
IPO price band	695 Rs. – 720 Rs.
LOT SIZE	20 shares
MINIMUM ORDER QUANTITY	20 shares
ISSUE SIZE	1513.60 Crore Rs.
OFFER FOR SALE	453.60 Crore Rs.
FRESH ISSUE	1060 Crore Rs.
LISTING AT	NSE, BSE
LISTING DATE	6th Aug, 2021

IMPORTANT DATES

IPO OPENING DATE	27th July, 2021
IPO CLOSING DATE	29th July, 2021
IPO ALLOTMENT DATE	3rd Aug, 2021
REFUNDS	4th Aug, 2021
DEMAT A/C CREDITED ON	5th Aug, 2021
IPO LISTING DATE	6th Aug, 2021

The Glenmark Life Sciences IPO begins for subscription from 27th July, 2021. The IPO subscription would continue till 29th July, 2021. The allotment status for the shareholders who applied would come on 3rd Aug, 2021. The refunds for the ones who did not get allotment would be initiated on 4th Aug, 2021. The DEMAT accounts of shareholders would be credited on 5th Aug, 2021. The listing of the company would be accompanied on 6th Aug, 2021.

PROMOTER AND LEAD MANAGERS

The promoters for Glenmark Life Sciences is the company Glenmark Pharmaceuticals itself.

The lead managers for the company are :

SBI Capital Markets Limited
DAM Capital Advisors Ltd.
Kotak Mahindra Capital Company Limited
BOB Capital Markets Limited
BoA Merrill Lynch
Goldman Sachs Securities Private Limited

The minimum lot size for the company is decided at shares. This holding accounts to Rs.. The maximum lot size is decided at shares. This amounts to Rs. . Hence the company’s final holdings would be set as :

	Shares	Amount
Minimum	20 shares	14400 Rs.
Maximum	260 shares	187200 Rs

OBJECTIVES FOR THE IPO

The money from the IPO can also be utilized to meet general corporate purposes.
There have been quite large outstanding dues on behalf of the promoter. This would help the company to be a debt free API business dominator.

COMPANY FINANCIALS

Particulars (in Million Rs.)	2020-21	2019-20	2018-19
ASSETS	19970	17256	14753
REVENUE	18859	15493	8868
NET PROFIT	3515	3130	1995
EPS	32.61	29.04	24.64

The company has been doing great on the financial front. There has been a constant growth in the company’s assets. The company has been making a rise of almost 1500 Crore Rs every year. On the other hand the revenue is increasing in outstanding amounts. The first rise of 1500 Crore Rs in Assets gave a boost of almost 6500 Crore Rs in revenue. Similarly the next 1500 Crore Rs gave a robust increase of 4000 Crore Rs on revenues.

One plus point for the company has been the COVID situation. However the profit margins have been the most impressive fronts for the company. Glenmark has been making constant 20% profits on the revenues. Thus making the company a better prospect to invest into. One can also think of going long term on the company as it has constant support from the promoter Glenmark Pharmaceuticals.